Preclinical and clinical pharmacology of cerivastatin

Cerivastatin, a new, entirely synthetic, and enantiomerically pure 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, is pharmacologically potent and hepatically selective, with an uncomplicated pharmacokinetic profile. In vitro and acute in vivo studies in animals demonstrated tha...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The American journal of cardiology 1998-08, Vol.82 (4), p.18J-25J
Hauptverfasser:	Bischoff, Hilmar, Heller, Allen H
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Arteriosclerosis - drug therapy Arteriosclerosis - metabolism Cardiovascular disease Cholesterol Clinical Trials, Phase I as Topic Dogs Drug Evaluation, Preclinical Drug therapy Enzymes Female Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology Lovastatin - pharmacokinetics Lovastatin - pharmacology Male Pharmacology Pyridines - pharmacokinetics Pyridines - pharmacology Rabbits Rats Safety
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!